Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.

Autor: Redondo-Calvo FJ; Department of Anesthesiology and Critical Care Medicine, University General Hospital, Ciudad Real, Spain.; Department of Medical Sciences (Pharmacology), School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.; School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain., Padín JF; Translational Research Unit, University General Hospital of Ciudad Real, Ciudad Real, Spain., Muñoz-Rodríguez JR; Department of Medical Sciences (Pharmacology), School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.; School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain., Serrano-Oviedo L; School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain., López-Juárez P; School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain., Porras Leal ML; Department of Internal Medicine, University General Hospital of Ciudad Real, Ciudad Real, Spain., González Gasca FJ; Department of Medical Sciences (Pharmacology), School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.; Department of Internal Medicine, University General Hospital of Ciudad Real, Ciudad Real, Spain., Rodríguez Martínez M; Department of Pharmacy, University General Hospital of Ciudad Real, Ciudad Real, Spain., Pérez Serrano R; Department of Pharmacy, University General Hospital of Ciudad Real, Ciudad Real, Spain., Sánchez Cadena A; Department of Pharmacy, University General Hospital of Ciudad Real, Ciudad Real, Spain., Bejarano-Ramírez N; Department of Medical Sciences (Pharmacology), School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.; Department of Paediatrics, University General Hospital of Ciudad Real, Ciudad Real, Spain., Muñoz Hornero C; Department of Internal Medicine, General Hospital of Puertollano, Puertollano, Spain., Barberá Farré JR; Department of Internal Medicine, University General Hospital of Alcazar de San Juan, Alcazar de San Juan, Spain., Domínguez-Quesada I; Department of Internal Medicine, University General Hospital of Alcazar de San Juan, Alcazar de San Juan, Spain., Sepúlveda Berrocal MA; Department of Internal Medicine, University General Hospital of Toledo, Toledo, Spain., Villegas Fernández-Infantes MD; Department of Internal Medicine, University General Hospital of Ciudad Real, Ciudad Real, Spain., Manrique Romo MI; Department of Internal Medicine, University General Hospital of Ciudad Real, Ciudad Real, Spain., Parra Comino Á; Translational Research Unit, University General Hospital of Ciudad Real, Ciudad Real, Spain., Pérez-Ortiz JM; Department of Medical Sciences (Pharmacology), School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.; School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain., Gómez-Romero FJ; Department of Medical Sciences (Pharmacology), School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.; School of Medicine at Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain.

Publikováno v: European journal of clinical investigation [Eur J Clin Invest] 2022 Jun; Vol. 52 (6), pp. e13776. Date of Electronic Publication: 2022 Apr 05.